Broadly Protective Pneumococcal Vaccine with Cardiac Protection

Tech ID:

With the emergence of pneumococcal infections caused by non-vaccine serotypes and multidrug resistant strains, this broadly effective vaccine may be the best strategy for decreasing morbidity and mortality. Because it also protects against adverse cardiac events during and after pneumococcal pneumonia, it has strong potential as a vaccine for seniors who already have cardiovascular disease and it provides an additional indication for a pneumococcal vaccine outside of the current vaccine recommendations. Phase 1 clinical study is ongoing.

This novel indication is part of a portfolio created in collaboration with St. Jude Children's Research Hospital and Univ. of Oklahoma.

Dr. Orihuela's research website:

More information about St. Jude Children's Research Hospital collaboration and related technologies:

Research paper describing the primary vaccine:

Recent Publication on Cardiac Microlesions:

Patent Information:
For information contact:
Daniel Rafferty
Business Development Manager
Office of Technology Commercialization
Carlos Orihuela
Elaine Tuomanen
Armand Brown